Chemoradiation Including Paclitaxel for Locally Recurrent Muscle-invasive Bladder Cancer in Elderly Patients

Käsmann, Lukas; Manig, Lisa; Rades, Dirk

doi:10.21873/invivo.11051

Cited by 5 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical data indicate that BCa has a high mortality rate, due to its propensity to recur and metastasize, and the absence of symptoms in the early stage of the disease ( 3 ). Therefore, early diagnosis and appropriate treatment is the key to improving survival in patients with BCa ( 4 , 5 ). With the lack of effective treatments and monitoring strategies, novel diagnostic markers and effective treatment strategies for BCa are imperative.…”

Section: Introductionmentioning

confidence: 99%

miR‑124 regulates STAT3‑mediated cell proliferation, migration and apoptosis in bladder cancer

Wang

Han

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

The etiology and pathogenesis of bladder cancer (BCa) is complex. MicroRNA (miRNA) has been implicated in BCa. Targeting of signal transducer and activator of transcription 3 (STAT3) by miR-124 to regulate tumorigenesis has been demonstrated in other types of cancer. In the present study, miR-124 levels were downregulated in the BCa T24 cell line and STAT3 was increased in BCa cell lines. Transfection of miR-124 mimics into T24 cells significantly inhibited STAT3 expression. A luciferase assay confirmed that miR-124 directly targeted the STAT3 3′untranslated region to inhibit STAT expression. Knockdown of STAT3 expression led to increased apoptosis of T24 cells and reduced tumor growth in vitro. The results demonstrated the molecular mechanisms and biological functions of the miR-124/STAT3 signal pathway at the cellular level and indicate the potential of miR-124 as a therapeutic target for BCa.

show abstract

Section: Introductionmentioning

confidence: 99%

miR‑124 regulates STAT3‑mediated cell proliferation, migration and apoptosis in bladder cancer

Wang

Han

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…Paclitxel is an anti-fibrotic, anti-proliferative drug that is used as a coating in minimally invasive vascular applications to prevent restenosis. 12,13,14 ROBUST I is a prospective study evaluating the safety and preliminary efficacy of DCB for urethral stricture.…”

Section: Introductionmentioning

confidence: 99%

A drug-coated balloon treatment for urethral stricture disease: Interim results from the ROBUST I study

Virasoro¹,

DeLong²,

Mann

et al. 2020

CUAJ

View full text Add to dashboard Cite

Introduction: We aimed to investigate the safety and preliminary efficacy of the OptilumeTM paclitaxel-coated balloon for the treatment of recurrent urethral stricture. Methods: Men with bulbar urethral strictures ≤2 cm with 1–4 prior endoscopic treatments were enrolled at four study sites after Ethics Committee approvals. All subjects were treated with mechanical balloon dilation or direct visualization internal urethrotomy prior to drug-coated balloon treatment. Patients were evaluated at 2–5 days, 14 days, three, six, and 12-months post-treatment. The primary safety endpoint was serious complications through 90 days post-procedure. The preliminary efficacy endpoint was anatomic success, defined as urethral lumen ≥14 Fr at 12 months. Results: A total of 53 subjects were enrolled and treated; 46 completed the 12-month followup. Forty-three percent of men had undergone >1 previous dilation; the mean for the overall study population was 1.7 prior dilations. There were no serious adverse events related to the treatment within 90 days. Anatomic success was achieved in 32/46 (70%; 95% confidence interval [CI] 54–82%) at 12 months. The 14 failures included seven cystoscopic recurrences, five retreatments, and two patients who exited the study early due to symptom recurrence. Conclusions: One-year data indicates the OptilumeTM paclitaxel-coated balloon is safe for the treatment of recurrent bulbar urethral strictures. Early efficacy results are encouraging and support further followup of these men through five years, as well as further investigation with a randomized trial.

show abstract

“…Paclitaxel is a microtubule inhibitor with anti-fibrotic and anti-proliferative properties; it is currently used as a coating on vascular stents to prevent restenosis with excellent success. [11][12][13] Additionally, preliminary animal studies have begun to investigate paclitaxel coating for ureteral stents to prevent stricture after anastomosis. 14 ROBUST I is a single-arm prospective, multicenter study evaluating outcomes after Optilume™ DCB treatment with 1-year results showing 70% anatomic success with no serious adverse events after 12 months.…”

Section: Introductionmentioning

confidence: 99%

A drug-coated balloon treatment for urethral stricture disease: Two-year results from the ROBUST I study

Mann

Virasoro

DeLong

et al. 2020

CUAJ

View full text Add to dashboard Cite

Introduction: Mechanical balloon dilation and direct visualization internal urethrotomy (DVIU) are the most widely used treatments for urethral stricture disease in the U.S., but recurrence rates are high, especially after re-treatment. This study investigates the safety and efficacy of the Optilume™ paclitaxel-coated balloon for the treatment of recurrent strictures. Methods: Men with recurrent bulbar strictures ≤2 cm with 1–4 prior endoscopic treatments were treated with the Optilume™ drug-coated balloon. Patients were evaluated within 14 days, three, six, 12, and 24 months post-treatment. The primary safety endpoint was serious urinary adverse events. The primary efficacy endpoint was ≥50% improvement in International Prostate Symptom Score (IPSS) at 24 months. Secondary outcomes included quality of life, erectile function, flow rate, and post-void residual urine volume. Results: A total of 53 subjects were enrolled and treated; 46 completed the 24-month followup. Forty-three percent of men had undergone >1 previous dilations, with a mean of 1.7 prior dilations. There were no serious adverse events related to treatment at two years. Success was achieved in 32/46 (70%), and baseline IPSS improved from a mean of 25.2 to 6.9 at 24 months (p<0.0001). Quality of life, flow rate, and post-void residual urine volumes improved significantly from baseline. There was no impact on erectile function. Conclusions: Two-year data indicates the Optilume™ paclitaxel-coated balloon is safe for the treatment of recurrent bulbar urethral strictures. Early efficacy results are encouraging and support further followup of these men through five years, as well as further investigation with a randomized trial.

show abstract

Chemoradiation Including Paclitaxel for Locally Recurrent Muscle-invasive Bladder Cancer in Elderly Patients

Abstract: Abstract. Background

Cited by 5 publications

References 8 publications

miR‑124 regulates STAT3‑mediated cell proliferation, migration and apoptosis in bladder cancer

miR‑124 regulates STAT3‑mediated cell proliferation, migration and apoptosis in bladder cancer

A drug-coated balloon treatment for urethral stricture disease: Interim results from the ROBUST I study

A drug-coated balloon treatment for urethral stricture disease: Two-year results from the ROBUST I study

Contact Info

Product

Resources

About